ProKidney Enters New $200M Sale Agreement with Jefferies
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ProKidney ( (PROK) ) has issued an update.
On July 14, 2025, ProKidney Corp. entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $200 million of its Class A common stock. This move replaces a previous agreement from January 2024 and provides ProKidney with flexibility in raising capital through an ‘at the market’ offering, potentially impacting its financial strategy and market positioning.
The most recent analyst rating on (PROK) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney Corp. operates in the healthcare industry, focusing on developing innovative treatments for kidney-related conditions. The company is involved in providing advanced medical solutions and therapies aimed at improving kidney health.
Average Trading Volume: 11,829,700
Technical Sentiment Signal: Buy
Current Market Cap: $1.33B
For an in-depth examination of PROK stock, go to TipRanks’ Overview page.
